Evaluation of [18F] florbetaben in subjects participating in the Parkinson's Progression Markers Initiative (PPMI) Protocol

Trial Profile

Evaluation of [18F] florbetaben in subjects participating in the Parkinson's Progression Markers Initiative (PPMI) Protocol

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Parkinson's disease
  • Focus Biomarker; Diagnostic use; Pharmacodynamics
  • Acronyms PPMI
  • Most Recent Events

    • 08 Jun 2017 Results of longitudinal analysis of PRECEPT and PPMI trials to estimate the degree of enrichment and impact of reduced dopamine transporter (DAT) binding as a biomarker on future trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top